MedPath
Found 132 clinical trials|View Analysis
Sort by:

Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma

Phase 3
Not yet recruiting
Conditions
Glioblastoma
Interventions
Biological: Dendritic Cell Vaccine
Combination Product: Pembrolizumab
Other: Placebo
First Posted Date
2024-12-27
Last Posted Date
2024-12-27
Lead Sponsor
University of Sao Paulo General Hospital
Target Recruit Count
186
Registration Number
NCT06749925

Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma

Phase 2
Recruiting
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Neoantigen-loaded Dendritic Cell Vaccine
Immune Checkpoint Inhibitors (ICIs)
Interventions
Biological: neoantigen-loaded dendritic cell vaccine (NeoDC-Vac)
First Posted Date
2024-11-05
Last Posted Date
2024-11-05
Lead Sponsor
Sichuan University
Target Recruit Count
165
Registration Number
NCT06675201
Locations
🇨🇳

West China Hospital of Sichuan University, Chengdu, Please Select, China

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Phase 2
Recruiting
Conditions
Advanced Fallopian Tube Carcinoma
Advanced Fallopian Tube High Grade Serous Adenocarcinoma
Advanced Ovarian Carcinoma
Advanced Ovarian Carcinosarcoma
Advanced Ovarian Clear Cell Adenocarcinoma
Advanced Ovarian Endometrioid Adenocarcinoma
Advanced Ovarian High Grade Serous Adenocarcinoma
Advanced Primary Peritoneal Carcinoma
Advanced Primary Peritoneal High Grade Serous Adenocarcinoma
Fallopian Tube Carcinosarcoma
Interventions
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
Procedure: Leukapheresis
Procedure: Magnetic Resonance Imaging
Biological: Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
Drug: Placebo Administration
Biological: Tetanus and Diphtheria Toxoids Adsorbed
First Posted Date
2024-10-15
Last Posted Date
2024-11-21
Lead Sponsor
Mayo Clinic
Target Recruit Count
78
Registration Number
NCT06639074
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast Cancer

Phase 1
Not yet recruiting
Conditions
Breast Neoplasms
Interventions
Biological: CircFam53B-219aa DC vaccine
Drug: camrelizumab
First Posted Date
2024-07-31
Last Posted Date
2024-07-31
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
48
Registration Number
NCT06530082

Sequential Immunochemotherapy Treatment With Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer

Phase 2
Not yet recruiting
Conditions
Microsatellite Stable Colorectal Carcinoma
Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Interventions
Biological: Autologous Dendritic Cell (DC) Vaccine
First Posted Date
2024-07-26
Last Posted Date
2024-07-26
Lead Sponsor
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Target Recruit Count
36
Registration Number
NCT06522919
Locations
🇮🇹

IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"-IRST S.r.l., Meldola, Forlì Cesena, Italy

🇮🇹

Pia Fondazione di Culto e Religione Azienda Ospedaliera "Card.G.Panico", Tricase, Lecce, Italy

Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

Early Phase 1
Recruiting
Conditions
Breast Cancer
Triple Negative Breast Cancer
Interventions
Procedure: Leukapheresis
Biological: Dendritic Cell (DC) Vaccine
First Posted Date
2024-05-30
Last Posted Date
2024-05-31
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
16
Registration Number
NCT06435351
Locations
🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

Phase 1
Suspended
Conditions
Endometrial Cancer
Cancer of Endometrium
Carcinoma of Endometrium
Endometrial Carcinoma
Interventions
Biological: AdHER2DC vaccine
Biological: Pembrolizumab
Drug: Lenvatinib
Biological: N-803
Device: PATHWAY HER2 (4B5) assay
First Posted Date
2024-02-12
Last Posted Date
2025-01-10
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
60
Registration Number
NCT06253494
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients

Phase 1
Recruiting
Conditions
Ovarian Cancer
Pancreas Cancer
Esophageal Cancer
Liver Cancer
First Posted Date
2023-07-27
Last Posted Date
2024-11-25
Lead Sponsor
University Hospital, Antwerp
Target Recruit Count
10
Registration Number
NCT05964361
Locations
🇧🇪

Antwerp University Hospital, Edegem, Belgium

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Phase 1
Recruiting
Conditions
Fallopian Tube Carcinosarcoma
Primary Peritoneal Carcinosarcoma
Recurrent Fallopian Tube Carcinoma
Recurrent Fallopian Tube Clear Cell Adenocarcinoma
Recurrent Fallopian Tube Endometrioid Adenocarcinoma
Recurrent Fallopian Tube High Grade Serous Adenocarcinoma
Recurrent Ovarian Carcinoma
Recurrent Ovarian Carcinosarcoma
Recurrent Ovarian Clear Cell Adenocarcinoma
Recurrent Ovarian Endometrioid Adenocarcinoma
Interventions
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Biological: Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
Biological: Pembrolizumab
Procedure: Pheresis
First Posted Date
2023-06-27
Last Posted Date
2024-11-26
Lead Sponsor
Mayo Clinic
Target Recruit Count
40
Registration Number
NCT05920798
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

Phase 1
Recruiting
Conditions
Triple Negative Breast Cancer
HER2-positive Breast Cancer
Leptomeningeal Disease
Interventions
Biological: Dendritic Cell Vaccine
First Posted Date
2023-04-12
Last Posted Date
2024-12-13
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
18
Registration Number
NCT05809752
Locations
🇺🇸

Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath